Teva Pharmaceuticals USA is recalling 32,543 cartons of Buprenorphine Transdermal System 5 mcg/hour (the generic version of Butrans). This recall was issued because laboratory tests showed the patches were releasing the medication at a slower rate than required by safety standards. This defect means patients may receive a lower dose of medication than prescribed, which could lead to inadequate pain management or withdrawal symptoms. These patches were distributed nationwide in the U.S. and Puerto Rico.
The patch is designed to release medication at a steady rate; however, these affected lots release the drug too slowly. This poses a risk of sub-therapeutic dosing, potentially causing a recurrence of pain or opioid withdrawal symptoms for patients who rely on this medication for chronic pain control.
Pharmacist consultation and refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.